J&J Multiple Myeloma Drug Talvey Shows Significant Mortality Risk Reduction in Trial

Johnson & Johnson's multiple myeloma drug, Talvey, has demonstrated a reduction in mortality risk by up to 53% in a late-stage clinical trial, according to new findings.